🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

Esperion Therapeutics Inc (ESPR)

NASDAQ
Currency in USD
Disclaimer
2.800
+0.330(+13.36%)
Closed
After Hours
2.830+0.030(+1.071%)

ESPR Comments

Andrea, ho 76 anni e come vedi sto ancora lavorando in chiusura mi è finalmente passata al vendita 2,30 e sto sistemando i movimenti di oggi, ma ormai sono sempre più stanco e mi sto portando sempre di più sul reddito fisso che è meno impegnativo anche se ci faccio trading.
Ti chiederai come sia finito ad Hong KONG : avevo Adr della società in usa e quando hanno dato l' annuncio che delistavano dagli usa per concentrare su Hong Kong la gente è andata in panic sell e ho rastrellato a 0,40 tutto quello che potevo, poi nel giro di 2-3 anni ho chiuso tutto a circa 64 dollari di HK ovvero allora 8 usd ( 20 volte tanto ),spesso è il detino che ti mette davanti le occasioni e bisogna saperle prendere. Per adesso mi accontenterei di fare x 20 anche con ESPR , se è vero che la storia si ripete ciclicamente......
anche ARQT è interessante
interessante anche ARQT
vedo che nel prosieguo ha fatto la in.cu.la.ta, meno male essere uscito sullo spike dei dati. Rientriamo a 1,9 ?
nel pre market ha scambiato a 2,87
2,95 $ !!! alle 6.26
🤔 18.6 Million Shares Short Interest is Real or Fake from MarketWatch 🤔
buyout soon! multibagger
Wow this is done for!
p o r c k o d j i o ?
opinions on this strange drop down?
why would some dumas short this stock? control freek
And boom! FDA approval makes it wirth 2,3, 5x??
Wtf.
Ready to POP. . Load up. .
still waiting for 40$ is it possible this year?
I think 20$ is hardly possible this year.
Does anyone look at even the financials? This company is a dumpster fire, and the dumpster is full of cash and debt.
Pre Market prise, what happened?
$ 10.17 seems to me a good opportunity for range-bounds traders.
3RD Most Shorted Stock.
They waited for 20 million in profit, but it turned out 8 only. CEO quietly mentioned that there are 30 million (!!!) not taken into this report. 2 payments were not included in the report from Daiichi and Oberland capital (30 mln)
I think ESPR has a lot of potential. Also a chance of a nice short squeeze.  https://www.moneyshow.com/articles/tptp2021-55871/
ESPR is heavily shorted. seems there will be short squeeze just like #GMO and #AMC
Buy opportunity
great keep going up
Buy and hold
Good buying opportunity. Got a huge gap to close at $68.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.